Ken Griffin’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$59.5M Buy
1,045,900
+869,400
+493% +$50.7M 0.01% 1386
2026
Q2
$10.3M Buy
176,500
+73,700
+72% +$4M ﹤0.01% 3532
2026
Q1
$5.97M Buy
102,800
+57,900
+129% +$3.14M ﹤0.01% 4046
2025
Q4
$2.07M Buy
44,900
+28,400
+172% +$1.27M ﹤0.01% 5841
2025
Q3
$594K Sell
16,500
-15,100
-48% -$500K ﹤0.01% 8703
2025
Q2
$1.03M Buy
31,600
+13,400
+74% +$439K ﹤0.01% 7026
2025
Q1
$687K Sell
18,200
-8,300
-31% -$664K ﹤0.01% 7784
2024
Q4
$2.17M Sell
26,500
-20,200
-43% -$2.01M ﹤0.01% 5458
2024
Q3
$5.34M Buy
46,700
+15,200
+48% +$1.37M ﹤0.01% 3835
2024
Q2
$2.38M Sell
31,500
-3,200
-9% -$218K ﹤0.01% 4998
2024
Q1
$2.37M Buy
34,700
+32,500
+1,477% +$2.25M ﹤0.01% 5193
2023
Q4
$138K Hold
2,200
– – ﹤0.01% 10514
2023
Q3
$112K Sell
2,200
-15,000
-87% -$740K ﹤0.01% 10747
2023
Q2
$859K Buy
17,200
+14,200
+473% +$673K ﹤0.01% 6773
2023
Q1
$112K Buy
3,000
+2,100
+233% +$89.1K ﹤0.01% 11086
2022
Q4
$43.2K Sell
900
-528,300
-100% -$20.7M ﹤0.01% 12313
2022
Q3
$12.7M Buy
+529,200
New +$13.4M ﹤0.01% 2421

Other funds holding PCVX

Ken Griffin's PCVX Position: Q3 2026 in Review

Ken Griffin opened a new position in Vaxcyte (PCVX) in Q3 2026: 154,204 shares worth $8.77M. The stake represents ﹤0.01% of the portfolio and ranks #3857 among its holdings. This is a return to the name: Ken Griffin previously reported a position in PCVX as recently as Q4 2025.

Ken Griffin first reported a position in PCVX in Q2 2020 and has held it in 21 quarters since. The position peaked at $40.8M in Q4 2022. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Ken Griffin held 154,204 shares of Vaxcyte worth $8.77M as of Q3 2026.
  • Vaxcyte was a new Ken Griffin position in Q3 2026.
  • Vaxcyte made up ﹤0.01% of Ken Griffin's portfolio in Q3 2026, its #3857 holding.
  • Ken Griffin first reported a position in Vaxcyte in Q2 2020 and has held it in 21 quarters since.
  • Ken Griffin's Vaxcyte position peaked at $40.8M in Q4 2022.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.